Neowise

Neowise Biotechnology is a company focused on the research and development of TCR-T cell therapy drugs for solid tumors. Utilizing its self-developed high-throughput antigen-antigen receptor screening technology, Neowise can quickly identify suitable targets for solid tumor treatment and formulate the most appropriate cell therapy solutions for patients. The core executive team of Neowise Biotechnology has many years of experience working in well-known pharmaceutical companies both in China and internationally. They possess extensive management and operational expertise across the entire chain, including bioinformatics prediction and analysis, neoantigen target discovery, TCR sequence discovery and validation, TCR-T production processes and CMC development, translational medicine, and clinical development.